High Dose Candesartan Versus Quinapril for Restenosis Prophylaxis After Stent Angioplasty
The study is designed to test the hypothesis that high dose candesartan treatment compared to quinapril is able to reduce intima hyperproliferation and the restenosis rate after stent angioplasty in peripheral occlusive artery disease...
Brief Summary
The study is designed to test the hypothesis that high dose candesartan treatment compared to quinapril is able to reduce intima hyperproliferation and the restenosis rate after stent angioplasty in peripheral occlusive artery disease.
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Detailed Clinical Trial Description
Patients are randomly assigned to treatment with either candesartan 32 mg/d or Quinapril 20 mg/d before the angioplasty. Walking distance, intima media thickness and crurobrachial pressure ratios are compared after 6 weeks, 3 months and 6 months. After 6 months an angiographic control is performed.
Intervention(s) in this Clinical Trial
- Drug: candesartan (drug) or quinapril (drug)
Outcome Measures for this Clinical Trial
Primary Measures
- Restenosis/reintervention after 6 months
Secondary Measures
- pain-free walking distance
- crurobrachial pressure ratios
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- male and female
- peripheral occlusive arterial disease Stad IIb Fontaine classification
Exclusion Criteria:
- patients with lesions not available for PTA
- renal insufficiency
- patients on calcium-antagonists
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 80 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: Dresden University of Technology Other
Overall Clinical Trial Officials and Contacts
Wilhelm Kirch, MD Study Chair Institute of Clinical Pharmacology
Additional Information
Information obtained from ClinicalTrials.gov on February 09, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00154050
Study ID Number: IKPD KARDCHEM 02-04
ClinicalTrials.gov Identifier: NCT00154050
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00154050
